These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8289501)

  • 1. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders.
    Campbell LJ; Garson OM
    Leukemia; 1994 Jan; 8(1):67-71. PubMed ID: 8289501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
    Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
    Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
    Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
    Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
    Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
    Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and cytogenetic features of 29 cases of myelodysplastic syndrome associated with del(20q)].
    Qin S; Liu SH; Bo LJ; Liu XP; Li CW; Dai Y; He GS; Shao ZH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Apr; 21(2):171-2. PubMed ID: 15079804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series.
    Pan J; Wu C; Xue Y; Qiu H; Chen S; Zhang J; Bai S; Wu Y; Wang Y; Shen J; Gong Y
    Cancer Genet; 2014 Mar; 207(3):51-6. PubMed ID: 24699042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
    Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
    Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
    Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
    Jung SW; Lee SY; Jekarl DW; Kim M; Lim J; Kim Y; Han K; Kim YJ; Cho SG; Song J
    Leuk Res; 2011 Jun; 35(6):735-40. PubMed ID: 21146871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly.
    Liu YC; Miyazawa K; Sashida G; Kodama A; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Aug; 169(1):69-72. PubMed ID: 16875940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?
    Wattel E; Laï JL; Hebbar M; Preudhomme C; Grahek D; Morel P; Bauters F; Fenaux P
    Leuk Res; 1993 Nov; 17(11):921-6. PubMed ID: 8231232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q.
    Smoley SA; Fink SR; Paternoster SF; Stockero KJ; Nguyen LP; Nguyen PL; Hanson CA; Dewald GW
    Cancer Genet Cytogenet; 2007 Mar; 173(2):144-9. PubMed ID: 17321330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-).
    Li T; Xue Y; Wu Y; Pan J
    Br J Haematol; 2004 May; 125(3):337-42. PubMed ID: 15086414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
    Ghaddar HM; Stass SA; Pierce S; Estey EH
    Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consecutive chromosomal studies in patients with myelodysplastic syndrome (MDS). Czechoslovak MDS Cooperative Group.
    Michalova K; Musilova J; Zemanova Z
    Ann Genet; 1991; 34(3-4):212-8. PubMed ID: 1809229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.